CAS Medical Systems, Inc. (CASM) Granted FDA 510(k) Clearance to Expand Labeling for FORE-SIGHT Cerebral Oximeter

QualityStocks would like to highlight CAS Medical Systems, Inc. (OTCBB: CASM). CAS Medical Systems is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The company's FORE-SIGHT Absolute Cerebral Oximeter is the first cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for neonates, infants, children and adults.

In the company’s news yesterday,

CAS Medical Systems, Inc. announced a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the labeling for its FORE-SIGHT(r) Cerebral Oximeter. The new labeling allows the Oximeter to be used on all patients, including those weighing less than 5.5 pounds.

The FORE-SIGHT Cerebral Oximeter is a Near Infra-Red Spectroscopy (NIRS) based device designed to non-invasively and continuously detect oxygen saturation changes in brain tissue, enabling clinicians to quickly react to potentially harmful events before they become serious. According to the company, FORE-SIGHT is the first and only device that provides a non-trend, absolute measure of cerebral tissue oxygen saturation for all patient populations regardless of age and weight.

“We currently use the FORE-SIGHT Cerebral Oximeter for clinical monitoring of term and near-term infants pre-ECMO and/or on ECMO, as well as infants with hypoxic-ischemic encephalopathy requiring cooling treatment for neuro-protection. Use of the FORE-SIGHT Cerebral Oximeter for patients below 2.5 kg will allow for clinical monitoring of smaller neonates potentially at risk for intra-ventricular hemorrhage, central apnea, and seizures,” stated Dr. K. Rais-Bahrami, Director of the Neonatal-Perinatal Fellowship Program at Children’s National Medical Center in Washington, DC.

Andrew E. Kersey, President and Chief Executive Officer of CASMED, added, “We are pleased with the FDA’s decision to expand clearance for the FORE-SIGHT Cerebral Oximeter to include patients below 2.5 kg. This expanded labeling will allow us additional access into the Neonatal ICU market, where a large percentage of at-risk patients have a low or very low birth weight. In conjunction with the unique benefits that the FORE-SIGHT small sensor offers — including COOL-LIGHT(tm) technology that protects fragile skin from heat, non-adhesive sensor solutions, and a very small sensor footprint — the new, expanded labeling uniquely positions CASMED for acceptance in the Neonatal arena.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.